Cart
sales@molnova.com
VU0360172
CAS No. 1310012-12-4
VU0360172( VU-0360172 | VU 0360172 )
Catalog No. M27938 CAS No. 1310012-12-4
VU0360172 is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 111 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 576 | In Stock |
|
| 100MG | 816 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVU0360172
-
NoteResearch use only, not for human use.
-
Brief DescriptionVU0360172 is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM).
-
DescriptionVU0360172 is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM).(In Vivo):VU0360172 stimulates polyphosphoinositide (PI) hydrolysis in vivo, which is abrogated in mGlu5 receptors gene deleted mice.
-
In Vitro——
-
In Vivo——
-
SynonymsVU-0360172 | VU 0360172
-
PathwayNeuroscience
-
TargetGluR
-
RecptorCK1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1310012-12-4
-
Formula Weight294.329
-
Molecular FormulaC18H15FN2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (283.13 mM)
-
SMILESFc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ana MARTíNEZ GIL, et al. Preparation of substituted benzothiazoles as casein kinase 1 inhibitors for the treatment of human diseases. WO2014114825A1
molnova catalog
related products
-
IDRA-21
IDRA-21 is a positive AMPA receptor modulator.?
-
MTEP hydrochloride
MTEP hydrochloride is non-competitive mGlu5 antagonist (IC50 and Ki of 5 nM and 16 nM respectively).
-
SIB-1757
SIB-1757 is a selective antagonist of mGlu5 metabotropic glutamate receptor subtype (hmGlu5, IC50 : 0.4 μM),SIB-1757 was given by either intrathecal (i.th.), subcutaneous (s.c.) or intraplantar (i.pl.) injection.?
